Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Repligen (RGEN) shares ended the last trading session 3.7% higher at $174.24. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...